Literature DB >> 20543605

Contribution of sexually transmitted infections to the sexual transmission of HIV.

Helen Ward1, Minttu Rönn.   

Abstract

PURPOSE OF REVIEW: We review recent evidence about the link between sexually transmitted infections (STI) and HIV transmission and consider implications for control programmes. RECENT
FINDINGS: New studies and meta-analyses confirm the association of HIV acquisition and transmission with recent STIs, although there is considerable heterogeneity between organisms and populations. Much of the recent evidence relates to herpes simplex virus type 2 (HSV-2), for which the population-attributable risk percentage (PAR%) for HSV-2 is between 25 and 35 in Africa. Mathematical models show how transmission attributable to STI varies with HIV epidemic phase, and HSV-2 becomes increasingly important as the epidemic matures. HSV-2 suppressive therapy reduces HIV concentrations in plasma and the genital tract in people coinfected with HSV-2, in part due to direct inhibition of HIV reverse transcriptase. Recent trials of HSV-2 suppressive therapy have not shown an impact on the risk of HIV acquisition, nor in controlling transmission from dually infected people to their serodiscordant heterosexual partners.
SUMMARY: Although there is a plausible link between STI and HIV risk, intervention studies continue to be disappointing. This fact does not disprove a causal link, but mechanisms of action and the design and implementation of interventions need to be better understood.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543605      PMCID: PMC2923028          DOI: 10.1097/COH.0b013e32833a8844

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  42 in total

Review 1.  Herpes simplex virus type 2: a key role in HIV incidence.

Authors:  Judith R Glynn; Samuel Biraro; Helen A Weiss
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

2.  Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group.

Authors:  M J Wawer; N K Sewankambo; D Serwadda; T C Quinn; L A Paxton; N Kiwanuka; F Wabwire-Mangen; C Li; T Lutalo; F Nalugoda; C A Gaydos; L H Moulton; M O Meehan; S Ahmed; R H Gray
Journal:  Lancet       Date:  1999-02-13       Impact factor: 79.321

3.  Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial.

Authors:  A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth
Journal:  Lancet       Date:  2003-02-22       Impact factor: 79.321

4.  Sexually transmitted infections among patients with acute HIV in North Carolina.

Authors:  Sandra I McCoy; Joseph J Eron; Joann D Kuruc; Ronald P Strauss; Pia D M Macdonald; Susan A Fiscus; John Barnhart; Christopher D Pilcher; Peter A Leone; William C Miller
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

Review 5.  Sexual transmission of HIV-1.

Authors:  Julie Fox; Sarah Fidler
Journal:  Antiviral Res       Date:  2009-10-27       Impact factor: 5.970

6.  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.

Authors:  Jared M Baeten; Lara B Strick; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum
Journal:  J Infect Dis       Date:  2008-12-15       Impact factor: 5.226

7.  Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda.

Authors:  Kristine E Johnson; Mark E Sherman; Victor Ssempiija; Aaron A R Tobian; Jonathan M Zenilman; Maire A Duggan; Godfrey Kigozi; David Serwadda; Maria J Wawer; Thomas C Quinn; Charles S Rabkin; Ronald H Gray
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

8.  Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial.

Authors:  H Grosskurth; F Mosha; J Todd; E Mwijarubi; A Klokke; K Senkoro; P Mayaud; J Changalucha; A Nicoll; G ka-Gina
Journal:  Lancet       Date:  1995-08-26       Impact factor: 79.321

Review 9.  Acyclovir: a new use for an old drug.

Authors:  Christophe Vanpouille; Andrea Lisco; Leonid Margolis
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

10.  Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.

Authors:  Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn
Journal:  Vaccine       Date:  2008-12-09       Impact factor: 3.641

View more
  137 in total

Review 1.  Secondary HIV prevention: novel intervention approaches to impact populations most at risk.

Authors:  Jennifer L Brown; Ralph J Diclemente
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

2.  Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women.

Authors:  Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon
Journal:  Immunity       Date:  2017-01-10       Impact factor: 31.745

3.  Photoinactivation of Neisseria gonorrhoeae: A Paradigm-Changing Approach for Combating Antibiotic-Resistant Gonococcal Infection.

Authors:  Ying Wang; Raquel Ferrer-Espada; Yan Baglo; Xueping S Goh; Kathryn D Held; Yonatan H Grad; Ying Gu; Jeffrey A Gelfand; Tianhong Dai
Journal:  J Infect Dis       Date:  2019-07-31       Impact factor: 5.226

Review 4.  Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world.

Authors:  Kartik K Venkatesh; Timothy P Flanigan; Kenneth H Mayer
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

5.  The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Authors:  Kieran Seay; Nazanin Khajoueinejad; Jian Hua Zheng; Patrick Kiser; Christina Ochsenbauer; John C Kappes; Betsy Herold; Harris Goldstein
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

6.  Who is Saying What on Twitter: An Analysis of Messages with References to HIV and HIV Risk Behavior.

Authors:  Sophie Lohmann; Ismini Lourentzou; Chengxiang Zhai; Dolores Albarracín
Journal:  Acta Investig Psicol       Date:  2018-04

7.  A Nonhuman Primate Model for Rectally Transmitted Syphilis.

Authors:  Cassandra Tansey; Chunxia Zhao; Andre Hopkins; Jana M Ritter; Yetunde F Fakile; Allan Pillay; Samantha S Katz; Lara Pereira; James Mitchell; Frank Deyounks; Ellen N Kersh; Janet M McNicholl; Sundaram Ajay Vishwanathan
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 5.226

8.  STD Partner Services to Monitor and Promote HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men.

Authors:  David A Katz; Julia C Dombrowski; Michael Barry; Dawn Spellman; Teal R Bell; Matthew R Golden
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

9.  The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV Infection.

Authors:  Harrell W Chesson; Kyle T Bernstein; Thomas L Gift; Julia L Marcus; Sharon Pipkin; Charlotte K Kent
Journal:  Sex Transm Dis       Date:  2013-05       Impact factor: 2.830

Review 10.  Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention.

Authors:  Melanie R Nicol; Joseph A Corbino; Mackenzie L Cottrell
Journal:  J Clin Pharmacol       Date:  2018-06-14       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.